← All trials
NCT05627518
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2022
- Primary completion
- Dec 30, 2022
- Completion date
- Jan 15, 2023
- First posted
- Nov 25, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 54
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cinclus Pharma AGLead sponsor
- CRS d.o.o.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.